HC Wainwright & Co. Assumes Elicio Therapeutics at Buy, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns assumes Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces a price target of $12.
October 26, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elicio Therapeutics receives a Buy rating from HC Wainwright & Co. with a price target of $12.
The Buy rating and price target of $12 announced by HC Wainwright & Co. for Elicio Therapeutics is a positive signal for the company. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100